First Light Asset Management LLC Has $38.29 Million Position in Health Catalyst, Inc. $HCAT

First Light Asset Management LLC grew its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 9.9% in the third quarter, Holdings Channel reports. The firm owned 13,436,220 shares of the company’s stock after purchasing an additional 1,206,039 shares during the period. Health Catalyst comprises approximately 3.6% of First Light Asset Management LLC’s holdings, making the stock its 7th biggest position. First Light Asset Management LLC owned 0.19% of Health Catalyst worth $38,293,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Health Catalyst by 2.9% in the third quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock worth $12,243,000 after buying an additional 119,117 shares in the last quarter. Geode Capital Management LLC boosted its stake in Health Catalyst by 11.4% during the second quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock valued at $6,269,000 after buying an additional 169,580 shares during the period. AMH Equity Ltd grew its position in Health Catalyst by 54.5% during the third quarter. AMH Equity Ltd now owns 660,000 shares of the company’s stock worth $1,881,000 after buying an additional 232,851 shares in the last quarter. HighMark Wealth Management LLC grew its position in Health Catalyst by 88.3% during the third quarter. HighMark Wealth Management LLC now owns 310,282 shares of the company’s stock worth $884,000 after buying an additional 145,532 shares in the last quarter. Finally, Zacks Investment Management increased its stake in Health Catalyst by 4.4% in the 3rd quarter. Zacks Investment Management now owns 287,304 shares of the company’s stock worth $819,000 after acquiring an additional 12,066 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Price Performance

Shares of Health Catalyst stock opened at $1.32 on Monday. The firm has a market capitalization of $97.14 million, a PE ratio of -0.52 and a beta of 1.77. The company has a current ratio of 1.89, a quick ratio of 1.89 and a debt-to-equity ratio of 0.62. Health Catalyst, Inc. has a 12 month low of $1.20 and a 12 month high of $5.06. The business’s 50-day moving average price is $2.05 and its 200-day moving average price is $2.55.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Thursday, March 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The firm had revenue of $74.68 million during the quarter, compared to the consensus estimate of $73.99 million. Health Catalyst had a negative return on equity of 4.30% and a negative net margin of 57.20%. Sell-side analysts forecast that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Key Health Catalyst News

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Revenue and some profitability metrics showed resilience: Q4 revenue slightly beat consensus ($74.68M vs. $73.99M) and the company reported full‑year revenue of $311.1M with Adjusted EBITDA of $41.4M — signals that core demand remains. Health Catalyst Reports Fourth Quarter and Year End 2025 Results
• Positive Sentiment: Some chart/analyst commentary suggests the stock may be finding technical support (hammer pattern) and that earnings‑estimate revisions could stabilize — a possible near‑term bottom for opportunistic buyers. HCAT May Find a Bottom Soon
• Neutral Sentiment: Management has launched a strategic review and the CEO would not rule out a potential sale — this could unlock value but also creates uncertainty around capital allocation and timing. Seeking Alpha: CEO declines to rule out sale
• Negative Sentiment: The quarter showed an EPS miss and continued negative margins — Q4 EPS missed estimates (reported ~$0.08 vs. consensus around $0.10), which undercut confidence in near‑term profitability. MarketBeat Q4 results summary
• Negative Sentiment: Q1 revenue guidance was lowered to $68.0M–$70.0M vs. consensus ~ $74.1M — the guidance shortfall appears to be the main driver of the selloff since it signals softer near‑term top‑line momentum. Earnings press release / guidance
• Negative Sentiment: Multiple sell‑side firms lowered price targets and moved to neutral/hold/equal‑weight (Citigroup to $1.75, Stephens and Stifel to $2.00), increasing downward pressure and reducing buy‑side conviction. Analyst price-target cuts (Benzinga)
• Negative Sentiment: Market reaction was amplified by heavy volume and headlines emphasizing the mixed print and management uncertainty, leading to sharp intraday selling despite the revenue beat. MSN: stock reaction

Analysts Set New Price Targets

HCAT has been the topic of several recent analyst reports. Stifel Nicolaus lowered their price target on Health Catalyst from $3.75 to $2.00 and set a “hold” rating on the stock in a report on Friday. Raymond James Financial set a $3.00 price objective on Health Catalyst in a report on Friday. Stephens decreased their price objective on shares of Health Catalyst from $3.50 to $2.00 and set an “equal weight” rating on the stock in a research report on Friday. Citigroup lowered their target price on shares of Health Catalyst from $2.75 to $1.75 and set a “neutral” rating on the stock in a research note on Friday. Finally, Cantor Fitzgerald cut their price target on shares of Health Catalyst from $4.00 to $3.00 and set a “neutral” rating for the company in a research note on Friday. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $3.16.

Health Catalyst Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.